The dengue virus measures about 11,000 nucleotide bases as an RNA particle. This genetic material codes for three structural proteins and seven others required for replication within human cells.
A female mosquito from the Aedes genus becomes the vector when it bites an infected person. The virus enters the mosquito's gut cells and spreads to its salivary glands over several days before injecting infectious saliva into a new host's bloodstream.
Symptoms typically emerge four to seven days after exposure. High fevers between 40 and 41 degrees Celsius often accompany generalized pain behind the eyes and severe muscle aches during this period.
Two vaccines currently available include Dengvaxia approved in 2016 and Qdenga authorized in 2022. Dengvaxia protects individuals aged six to forty-five years while Qdenga suits people four years old and older regardless of prior infection status.
Dengue is endemic in more than one hundred countries across every continent except Antarctica as of March 2023. The Americas, Southeast Asia, and Western Pacific regions bear the heaviest burden with billions at risk annually.
Benjamin Rush coined break-bone fever in 1789 after reporting on muscle and joint pains experienced during the Philadelphia epidemic. The term originated from West Indian Spanish derived from Kiswahili dinga meaning cramp-like seizure caused by evil spirits.